Phase Ib trial of CALAA 01 to investigate an alternative dosing regimen in patients with solid tumours that are refractory to standard-of-care therapies.

Trial Profile

Phase Ib trial of CALAA 01 to investigate an alternative dosing regimen in patients with solid tumours that are refractory to standard-of-care therapies.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2012

At a glance

  • Drugs CALAA 01 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Calando Pharmaceuticals
  • Most Recent Events

    • 30 Aug 2012 Status changed from planning to active, no longer recruiting, according to an Arrowhead Research Corporation media release.
    • 15 Aug 2012 Additional patients were dosed, according to an Arrowhead Research Corporation media release.
    • 16 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top